Drugs / Meningococcal A and C Polysaccharide Conjugate Vaccine
Meningococcal A and C Polysaccharide Conjugate Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05252715 Comparator | Dec 2021 → Aug 2023 | meningococcal meningitis | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal A and C Polysaccharide Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252715 ↗ |
| Modality | Vaccine | “Meningococcal A and C Polysaccharide Conjugate Vaccine” NCT05252715 ↗ |
| Route | Intramuscular | “Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.” NCT05252715 ↗ |